{"issuance_frequency":"","notes_translated":{"fr":"Dans les 15 jours suivant le jour de l'octroi de la licence obligatoire ou de la conclusion de l'accord d'approvisionnement, selon la plus tardive des deux dates, l'entreprise pharmaceutique doit remplir le formulaire « Déclaration solennelle en vertu de l'alinéa 21.16(1)b) de la Loi sur les brevets » et la présenter au titulaire du brevet et au commissaire aux brevets.","en":"Within 15 days of the day on which the compulsory licence was granted or the supply agreement was signed, whichever is later, the pharmaceutical company must complete and submit to the patent holder and the Commissioner of Patents a \"Solemn or Statutory Declaration Under Paragraph 21.16(1)(b) of the Patent Act\". "},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"ce476c08-93ec-4a51-9912-c913b866f796","metadata_created":"2020-09-17T19:30:48.887476","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2020-09-17T19:30:48.887482","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2020-09-17","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Régime canadien d'accès aux médicaments","déclaration de la valeur monétaire et du nombre d'unités vendues","licence obligatoire","accord d'approvisionnement"],"en":["Canada's Access to Medicines Regime","declaring monetary value and units sold","compulsory licence","supply agreement"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"Déclaration de la valeur monétaire et du nombre d'unités vendues : Régime canadien d'accès aux médicaments","en":"Declaring monetary value and units sold under Canada's Access to Medicines Regime"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"ce476c08-93ec-4a51-9912-c913b866f796","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"30020ff3-61e0-4118-bf87-28089fe5c0a6","related_relationship":"","name_translated":{"fr":"Déclaration de la valeur monétaire et du nombre d'unités vendues : Régime canadien d'accès aux médicaments","en":"Declaring monetary value and units sold under Canada's Access to Medicines Regime"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Declaring monetary value and units sold under Canada's Access to Medicines Regime","language":["en"],"created":"2020-09-17T19:30:49.012445","url":"https://www.canada.ca/en/health-canada/services/canada-access-medicines-regime/companies/forms/declaring-monetary-value-units-sold.html","last_modified":null,"position":0,"revision_id":"e6eb61bc-f0d6-496b-af86-076745296245","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"ce476c08-93ec-4a51-9912-c913b866f796","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"885d2071-3438-4bc0-831e-65bdb980da7b","related_relationship":"","name_translated":{"fr":"Déclaration de la valeur monétaire et du nombre d'unités vendues : Régime canadien d'accès aux médicaments","en":"Declaring monetary value and units sold under Canada's Access to Medicines Regime"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Declaring monetary value and units sold under Canada's Access to Medicines Regime","language":["fr"],"created":"2020-09-17T19:30:49.012452","url":"https://www.canada.ca/fr/sante-canada/services/regime-canadien-acces-medicaments/entreprises/formulaires/declaration-valeur-monetaire-nombre-unites-vendues.html","last_modified":null,"position":1,"revision_id":"e6eb61bc-f0d6-496b-af86-076745296245","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2017-04-28 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"ce476c08-93ec-4a51-9912-c913b866f796","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"Within 15 days of the day on which the compulsory licence was granted or the supply agreement was signed, whichever is later, the pharmaceutical company must complete and submit to the patent holder and the Commissioner of Patents a \"Solemn or Statutory Declaration Under Paragraph 21.16(1)(b) of the Patent Act\". ","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Declaring monetary value and units sold under Canada's Access to Medicines Regime","revision_id":"e6eb61bc-f0d6-496b-af86-076745296245"}